Dr. Tao Li 李涛
Chief Physician
Department of Bone and Soft Tissue Surgery, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment and reconstruction of bone tumors, bone metastases, and soft tissue sarcomas. Management of skin malignancies including melanoma, squamous cell carcinoma, and basal cell carcinoma.
Dr. Li is Chief Physician at Zhejiang Cancer Hospital and Director of the Malignant Melanoma Diagnosis and Treatment Center at Zhejiang Cancer Center. Dr. Li received the Third Prize of Zhejiang Medical and Health Science and Technology Innovation Award. Research interests include bone, soft tissue, and skin malignancies. Dr. Li co-edited Soft Tissue Tumors and other texts.
Professional roles
- Member, Sarcoma Professional Committee, China Anti-Cancer Association
- Deputy Leader, Soft Tissue Tumor Group, China Anti-Cancer Association
- Chair, Skin Tumor Professional Committee, Zhejiang Anti-Cancer Association
- Vice Chair, Bone and Soft Tissue Tumor Professional Committee, Zhejiang Anti-Cancer Association
Name order: in Chinese the family name comes first (Li Tao). Papers usually list the name as Tao Li or Li T.
Selected publications
55 papers on PubMed matched by name and affiliation; 11 as first or senior author since 2016. Most recent first- or senior-author papers:
- Oncologist, 2026 (senior author): Conversion-intent PD-1-based chemoimmunotherapy restores surgical feasibility in borderline resectable or unresectable non-head-and-neck cutaneous squamous cell carcinoma. PubMed 42523185
- J Dermatolog Treat, 2025 (senior author): Neoadjuvant plus adjuvant dabrafenib and trametinib versus adjuvant dabrafenib and trametinib in patients with stage III melanoma: a single-center retrospective cohort study. PubMed 41290590
- J Dermatol, 2025 (senior author): Is One Year Enough? Extended Adjuvant Dabrafenib Plus Trametinib for Chinese Patients With Resected Stage III Melanoma. PubMed 40366077
- Clin Cancer Res, 2024 (first author): First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial. PubMed 38483309
- Sci Rep, 2024 (senior author): Comprehensive insights on genetic alterations and immunotherapy prognosis in Chinese melanoma patients. PubMed 39025927
- Anal Cell Pathol (Amst), 2023 (senior author): Functional Role of RBP in Osteosarcoma: Regulatory Mechanism and Clinical Therapy. PubMed 37426488
- Front Oncol, 2021 (senior author): Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma. PubMed 34221994
- Invest New Drugs, 2020 (first author): Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study. PubMed 32072356
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion